Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€3.89

€3.89

-0.510%
-0.02
-0.510%
-
 
31.05.24 / Frankfurt WKN: A2DS5F / Name: Valbiotis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Valbiotis Stock

Valbiotis shows a slight decrease today, losing -€0.020 (-0.510%) compared to yesterday.
So far the community has only identified positive things for Valbiotis stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Valbiotis in the next few years

Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Valbiotis vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Valbiotis -0.510% - - - - - -
Cerenis Therapeutics Holding S.A. 0.180% -0.887% 16.580% -9.106% -9.253% -18.868% 257.188%
Sensorion SA -0.820% -6.186% 7.692% 185.490% 82.000% -63.527% -
Genoway S.A. Inh. -1.920% -1.687% 4.082% 7.368% -7.483% 9.091% 131.818%

News

Valbiotis launches its e-commerce site  for the marketing of Valbiotis®PRO Cholestérol: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
Valbiotis publishes its annual accounts 2023: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis publishes its annual accounts 2023
Valbiotis publishes its annual accounts 2023
Valbiotis to launch its 100% natural dietary supplement  for the management of hypercholesterolemia  on the French market in May: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May